Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of
Provided By GlobeNewswire
Last update: Apr 11, 2025
Presentation highlighted the recent expansion of the Phase 3 SELVA trial to include children 3 to 5 years old
Presentation reviewed clinically and statistically significant Phase 2 results and the design of the ongoing Phase 3 SELVA trial
Read more at globenewswire.comNASDAQ:PVLA (6/3/2025, 6:02:00 PM)
24.44
-0.7 (-2.78%)
Find more stocks in the Stock Screener
